

Temporary benefits added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Novo-Norfloracin 400 mg Tablet (DIN 02237682) manufactured by Teva Canada Limited, Norflox 400 mg Tablet (DIN 02229524) manufactured by AA Pharma Inc., will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of **May 2, 2018**, all claims for Norflox 400 mg Tablet (DIN 02229524) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at www.ab.bluecross.ca/providers/pharmacy-home.html.

If this situation continues to be a long-term matter then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics, and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

Due to the unavailability of the products below, Apo-Mometasone 50 mcg/Dose Aqueous Nasal Spray (DIN 02403587) manufactured by Apotex Inc. and Sandoz Mometasone 50 mcg/Dose Aqueous Nasal Spray (DIN 02449811) manufactured by Sandoz Canada Inc., will be considered as temporary benefits for the *ADBL*.

DIN	Product description	Manufacturer
02238796	Apo-Beclomethasone 50 mcg/Dose Nasal Spray	Apotex Inc
02239288	Apo-Flunisolide 25 mcg/Dose Nasal Spray	Apotex Inc
02172712	Mylan-Beclo AQ. 50 mcg/Dose Meter Dose Nasal Spray	Mylan Pharmaceuticals ULC
02230648	Mylan-Budesonide AQ 100 mcg/Dose Nasal Spray	Mylan Pharmaceuticals ULC
02035324	Rhinocort 100 mcg Turbuhaler	Astrazeneca Canada Inc

As of **April 10, 2018**, all claims for Apo-Mometasone 50 mcg/Dose Aqueous Nasal Spray (DIN 02403587) and Sandoz Mometasone 50 mcg/Dose Aqueous Nasal Spray (DIN 02449811) will be adjudicated to the price published in the most recent *ABCDPL* until further notice. The *ABCDPL* is available online at www.ab.bluecross.ca/providers/pharmacy-home.html.

If this situation continues to be a long-term matter then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics, and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

... continued from previous page

Product supply shortage addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Pharmascience Inc. and Sterimax Inc. that the shortages pms-Tetrabenazine 25 mg Tablet (DIN 02402424) and Tetrabenazine 25 mg Tablet (DIN 02410338), respectively have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **June 4, 2018**.

TETRABENAZINE

25 MG TABLET

00002407590	APO-TETRABENAZINE	APX	\$ 3.3746
00002402424	PMS-TETRABENAZINE	PMS	\$ 3.3746
00002410338	TETRABENAZINE	STM	\$ 3.3746
00002199270	NITOMAN	VCL	\$ 7.2138

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit ab.bluecross.ca/providers/pharmacy-home.php



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.742 2018/05

